Empower Cells, Change Lives
Recent News
Triumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering
AUSTIN, TX, and HAMILTON, ON, March 13, 2019 – Triumvira Immunologics, Inc., (Triumvira) a privately held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced the appointment of Cynthia Molina as Vice...
read moreQ&A with Dr. Paul Lammers, President and CEO of Triumvira Immunologics developing their T-Cell Antigen Coupler Technology to activate T-Cells in the treatment of Advanced Hematological Cancers and Solid Tumors
Dr. Paul Lammers President & Chief Executive Officer Triumvira Immunologics www.triumvira.com Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published - March 4, 2019 CEOCFO: Dr. Lammers, you have been president and CEO for a little over a year...
read moreKnight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical...
read more